tracken
Penumbra, Inc. Aktie News
Neutral
PRNewsWire
●
13 Tage alt
ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.
Positiv
Investors Business Daily
●
26 Tage alt
Penumbra stock skyrocketed Thursday after the medtech company beat third-quarter expectations on the back of its blood-clot-removing tech.
Neutral
Seeking Alpha
●
26 Tage alt
Penumbra, Inc. ( PEN ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Cecilia Furlong Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Maggie Yuen - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, L...
Neutral
PRNewsWire
●
27 Tage alt
ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.
Neutral
PRNewsWire
●
29 Tage alt
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation Results of STORM-PE demonstrating superior efficacy of CAVT with anticoagulati...
Neutral
PRNewsWire
●
etwa ein Monat alt
ALAMEDA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients wi...
Neutral
Seeking Alpha
●
etwa ein Monat alt
Penumbra, Inc. (NYSE:PEN ) Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 October 26, 2025 7:00 PM EDT Company Participants Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President James Benenati - Chief Medical Officer Conference Call Participants Robert Lookstein William Plovanic - Canaccord Genuity Corp., Research Division Rachel Rosovsky Stavros Konstantinides...
Positiv
Investors Business Daily
●
etwa ein Monat alt
Penumbra unveiled the results of a study on Sunday showing its device is superior to blood thinners in pulmonary embolism patients.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
